Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)
Launched by JOHNS HOPKINS UNIVERSITY · Feb 9, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Expanding HOPE Kidney study, is exploring how kidney transplants from donors with HIV affect patients who also have HIV. The goal is to understand whether receiving a kidney from an HIV-positive donor leads to different outcomes, such as rejection of the kidney, compared to receiving a kidney from a donor without HIV. Researchers are particularly interested in the long-term effects of these transplants on patients' health.
To participate in this study, individuals must be at least 18 years old, have a documented HIV infection, and meet certain health criteria, like having a stable immune system indicated by a specific blood test. Participants should not have serious health issues that could complicate their treatment or the study. Those who join can expect to receive regular check-ups and support throughout the trial to monitor their health and the success of the transplant. This study aims to provide important insights that could improve kidney transplant options for people living with HIV.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participant meets local criteria for kidney transplant.
- • Participant is able to understand and provide informed consent.
- • Participant has documented HIV infection by any licensed assay or documented history of detectable HIV-1 RNA.
- • Participant is ≥ 18 years old.
- • HIV-1 RNA \< 50 copies/mL. Viral blips between 50-400 copies will be allowed as long as there are not consecutive measurements \> 200 copies/mL.
- • Participant is not suffering from significant wasting (e.g. body mass index \<21) thought to be related to HIV disease.
- Exclusion Criteria:
- • Participant has prior progressive multifocal leukoencephalopathy (PML), cryptosporidiosis of \> 1 month, or primary central nervous system (CNS) lymphoma.
- • Participant is pregnant or breastfeeding.
- • Past or current medical problems or findings from medical history, physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Boston, Massachusetts, United States
New York, New York, United States
Los Angeles, California, United States
Birmingham, Alabama, United States
Baltimore, Maryland, United States
New Orleans, Louisiana, United States
Chicago, Illinois, United States
Pittsburgh, Pennsylvania, United States
New Haven, Connecticut, United States
New York, New York, United States
San Diego, California, United States
New York, New York, United States
New York, New York, United States
Patients applied
Trial Officials
Christine Durand, MD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported